Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

14.17
-1.0010-6.60%
Volume:2.78M
Turnover:39.59M
Market Cap:1.96B
PE:-3.92
High:14.99
Open:14.91
Low:14.00
Close:15.17
52wk High:15.87
52wk Low:4.82
Shares:138.00M
Float Shares:107.00M
Volume Ratio:0.92
T/O Rate:2.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:23.13
PE(LYR):-4.60

Loading ...

Definium's LSD-based depression pill delivers strong late-stage results, shares surge

Reuters
·
Jun 22

Unusually active option classes on open June 16th

TIPRANKS
·
Jun 16

Compass Pathways targets late 2027 approval for treatment-resistant depression psychedelic therapy

Reuters
·
Jun 05

Compass Pathways grants 157,000 inducement stock options at USD 14.19 per share

Reuters
·
Jun 05

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 05

Hypha Labs flags cannabis-like growth pattern emerging in psychedelic industry

Reuters
·
Jun 04

Stock Track | COMPASS Pathways Soars 9.84% Intraday on Board Appointment Signaling Stronger Commercialization Strategy

Stock Track
·
Jun 02

Is COMPASS Pathways (CMPS) Recasting Its Commercialization Strategy With Kathleen Tregoning’s Board Appointment?

Simply Wall St.
·
Jun 01

Compass Pathways files Form 3 initial beneficial ownership statement for director Kathleen Tregoning

Reuters
·
May 30

COMPASS Pathways PLC call volume above normal and directionally bullish

TIPRANKS
·
May 30

Compass Pathways shareholders re-elect Justin Gover as director at AGM

Reuters
·
May 28

Compass Pathways elects Kathleen Tregoning to board of directors

Reuters
·
May 28

Compass Pathways Elects Kathleen Tregoning to Board of Directors

THOMSON REUTERS
·
May 28

Compass Pathways to join Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 26

Compass Pathways Is Maintained at Buy by Maxim Group

Dow Jones
·
May 16

Why COMPASS Pathways (CMPS) Is Up 13.1% After FDA Fast-Track Moves For COMP360 Profit Shift

Simply Wall St.
·
May 15

Compass Pathways Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 15

Compass Pathways price target raised to $17 from $16 at Morgan Stanley

TIPRANKS
·
May 15

Jefferies Remains a Buy on COMPASS Pathways (CMPS)

TIPRANKS
·
May 14

RBC Raises Price Target on COMPASS Pathways to $22 From $21, Keeps Outperform, Speculative Risk

MT Newswires Live
·
May 14